Indian Journal of Dermatology Venereology & Leprology最新文献

{"title":"Combined biological therapy with dupilumab and secukinumab for coexisting bullous pemphigoid and psoriasis.","authors":"Shan Cao, Baoqi Yang, Yongxia Liu, Hong Liu, Furen Zhang","doi":"10.25259/IJDVL_1291_2024","DOIUrl":"https://doi.org/10.25259/IJDVL_1291_2024","url":null,"abstract":"","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"1-3"},"PeriodicalIF":3.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Blaschkoid lichen planus pigmentosus on face.","authors":"Singamsetty Sushma, Kollipara Haritha, Gandikota Raghu Rama Rao, Sudhir Babu K","doi":"10.25259/IJDVL_709_2024","DOIUrl":"https://doi.org/10.25259/IJDVL_709_2024","url":null,"abstract":"","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"1"},"PeriodicalIF":3.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological and management outcome in 70 patients with pityriasis rubra pilaris: A retrospective analysis.","authors":"Nermin Karaosmanoglu, Pınar Ozdemir Cetinkaya, İsmail Yüksel","doi":"10.25259/IJDVL_1607_2024","DOIUrl":"https://doi.org/10.25259/IJDVL_1607_2024","url":null,"abstract":"<p><p>Background Pityriasis rubra pilaris (PRP) is a rare papulosquamous disease with a characteristic clinical appearance, including follicular salmon-coloured papules, which can sometimes progress into erythroderma. Both clinical and histopathological findings are important in diagnosing the disease and should be evaluated together. Objectives There are no guidelines for diagnosis and treatment of the disease. The aim of the present study was to contribute to the clinical diagnosis and treatment approach of this rare disease, which could serve as a clinical guide for dermatologists. Methods A total of 70 patients diagnosed with PRP in the last 20 years were included in this retrospective study. Clinical, demographic, and histopathologic profiles; and treatment strategies were analysed. Patients were divided into two groups with 'definite' or 'probable' diagnoses; those diagnosed to have PRP based on both clinical and histopathological findings were classified as having a 'definite' diagnosis; and those with histopathologically non-specific features but clinical findings compatible with PRP were classified as having a 'probable' diagnosis. Results Forty (57.1%) patients were females and 30 (42.9%) were males. Their age ranged from 8 to 79 years (mean age 39.57±18.80 years). The median duration of the disease (before patients received the diagnosis) was 7 months (IQR=24). According to biopsy reports, the most common epidermal changes were hyperkeratosis (78.6%) and focal parakeratosis (75.7%), while the 'checkerboard pattern,' which is considered specific for the disease, was detected in only 16 (22.9%) cases. Only 8 biopsy samples (11.4%) had an eosinophilic infiltrate. While 47 (67.1%) patients were classified under 'definite diagnosis and 23 (32.9%) were classified under 'probable diagnosis.' The disease duration was longer in patients with definite diagnosis than in patients with probable diagnosis (p=0.045). A total of 33 (47.14%) patients needed systemic therapy in addition to topical treatment. While 4 of these 33 patients were classified as Type 3, the remaining patients were classified as Type 1, classical adult type. Only three Type 1 (classical adult PRP) patients had erythroderma. Oral retinoids, especially acitretin, were the most preferred and effective treatment. Five patients showed improvement with methotrexate and two needed biological agents. Limitation The present study is retrospective and includes a relatively limited number of patients. Conclusion PRP is still a rare, difficult-to-manage disease. More studies are required to standardise and improve the diagnosis and treatment approaches for the disease.</p>","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"1-7"},"PeriodicalIF":3.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144057664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of intralesional triple combination versus intralesional triamcinolone acetonide for the treatment of keloids: A randomised controlled trial.","authors":"T Sanjay Kumar Menon, Jude Ernest Dileep, Sheela Kuruvila, Damayandhi Kaliyaperumal, Ilakkia Priya Sadasivam, Sushmitha Dharanisankar, Gayathri Jayabalan, Divya Mani","doi":"10.25259/IJDVL_1263_2024","DOIUrl":"https://doi.org/10.25259/IJDVL_1263_2024","url":null,"abstract":"<p><p>Background Treatment of keloids presents a significant therapeutic challenge due to their tendency to recur and their impact on a patient's quality of life. This randomised controlled trial aimed to compare the effectiveness of intralesional triple combination regimen versus intralesional triamcinolone acetonide monotherapy in treating keloids. Aims To compare the efficacy and safety of intralesional triple combination versus intralesional triamcinolone acetonide monotherapy in treating keloids at any site. Methods This study was conducted in the outpatient department of Dermatology, Venereology and Leprosy in a tertiary care hospital at Puducherry. Seventy two patients aged ≥18 years with a clinical diagnosis of keloids of any duration, involving any site and without any prior treatment were included in the study. Patients were randomised into two groups: Group A received intralesional triple combination (triamcinolone acetonide, 5-fluorouracil and hyaluronidase), while Group B received intralesional triamcinolone acetonide monotherapy. Treatments were administered every three weeks for four sessions or till complete flattening, whichever was earlier. The Vancouver Scar Scale was used for assessment at baseline and every three weeks for four sessions, and monthly for three months post treatment. Results Both groups showed significant improvement in the Vancouver Scar Scale scores at each follow-up compared to baseline. The mean (percentage) improvement in the Vancouver Scar Scale score in Group A was 0.58 ± 0.5 (7.08%) at three weeks, which progressively increased to 4.47 ± 1.29 (54.55%) at the final follow-up. In Group B, the improvement was lesser, with 0.08 ± 0.28 (0.95%) at three weeks, increasing to 3.08 ± 0.81 (36.65%) at the final follow-up. This improvement was significantly more in Group A at all time points compared to Group B (p < 0.05). Post-procedure pain, which lasted for a few hours, was noted in three and two patients in Groups A and B, respectively (p = 0.642). None of the patients had a recurrence of keloids during the study. Limitations Limitations of this study include small sample size, single centre design, short follow-up period, lack of blinding and patient-reported outcome measures, which may impact the generalisability of the findings. Conclusion Intralesional triple combination is more effective than triamcinolone acetonide monotherapy in treating keloids, offering significantly superior improvements in the Vancouver Scar Scale scoring.</p>","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"1-7"},"PeriodicalIF":3.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144065132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut microbiome in dermatology - A narrative review.","authors":"Varadraj Vasant Pai, Aswathy Panikaparambil Sarath, Zenia Kerkar","doi":"10.25259/IJDVL_1094_2024","DOIUrl":"https://doi.org/10.25259/IJDVL_1094_2024","url":null,"abstract":"<p><p>The gut microbiome and human body have co-evolved in a synergistic host-microbial relationship. The ideal composition of human gut microbiota is an elusive concept, but every individual has a unique gut microbiota profile with regional differences. Newer diagnostic techniques have helped identify different bacteria and their roles in health and disease. The gut microbiome composition is affected by various factors like age, diet, immune system, environmental factors, exercise, and drugs. The microbiome has varied roles in metabolism, immune response, immune tolerance and antimicrobial protection. Diet plays an important role in maintaining the gut microbial diversity. Loss of homoeostasis in the microbiome results in dysbiosis. Dysbiosis plays a role in many dermatological diseases like atopic dermatitis, psoriasis, acne, rosacea, hidradenitis suppurativa, connective tissue disorders and many other systemic conditions like obesity, diabetes, neurological disease and malignancy. Reconstitution of the gut microbiome ecology in the form of bacteriotherapy with the reintegration of certain strains of microbiota has a beneficial role in many of these disorders.</p>","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"1-11"},"PeriodicalIF":3.2,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unilateral naevoid telangiectasia: A retrospective study of 11 paediatric cases.","authors":"Rui He, Nan Zhang, Wu Guo, Lin Ma, Zigang Xu, Bin Zhang","doi":"10.25259/IJDVL_13_2024","DOIUrl":"10.25259/IJDVL_13_2024","url":null,"abstract":"<p><p>Background Unilateral naevoid telangiectasia (UNT) is a rare disease with only sporadic cases reported. The pathogenesis remains elusive and especially in paediatric patients, effective and safe treatment is still uncertain. Objectives The purpose of this study was to summarise the clinical characteristics of UNT, explore the possible pathogenesis and evaluate the efficacy and safety of pulsed dye laser (PDL) therapy. Methods The epidemiological data, clinical manifestations, laboratory tests and pathological features of paediatric patients with UNT were retrospectively reviewed. PDL treatment was done on some of the patients. Clinical documents and patient images before and after treatment were assessed to evaluate efficacy and adverse events. Results Most of the cases (9/11) presented with unilateral lesions. The laboratory results of all the 11 cases were normal. Histological examination in six cases revealed multiple, dilated veins in the reticular dermis. Vascular endothelial growth factor (VEGF) staining was positive, whereas oestrogen receptor staining was negative. Nine cases were treated with PDL which was shown to be effective and safe. Conclusion UNT has typical clinical manifestations. The pathogenesis of this disease could be linked to VEGF; however, more research and confirmation are needed. PDL is an effective and safe treatment for UNT.</p>","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"217-221"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinico-epidemiological characteristics and long-term surgical outcome of basal cell carcinoma treated with standard excision in patients of skin of colour: A retrospective study from Northern India.","authors":"Keshavamurthy Vinay, Hitaishi Mehta, Debajyoti Chatterjee, Ashwini Reddy, Sejal Jain, Tarun Narang, Sunil Dogra","doi":"10.25259/IJDVL_717_2023","DOIUrl":"10.25259/IJDVL_717_2023","url":null,"abstract":"<p><p>Background There is scant data on basal cell carcinoma (BCC) in Indian patients. This retrospective study was conducted to explore epidemiology, risk factors, clinical and pathological aspects, and long-term treatment outcomes of BCC in a cohort of North Indian patients. Methods Data about patients registered in the dermatosurgery clinic between 01 January 2017 and 31 December 2022 with a confirmed diagnosis of BCC was collected. Results Among the 83 patients, 56.6% were females, and the median age was 62 years (6-85 years). Most patients (81.9%) had a single BCC lesion, resulting in a total of 126 assessed lesions. The median size of BCC at presentation was 1.90 cm, with nodular BCC being the most common histopathological subtype (39.7%). Head and neck region involvement was observed in 82.5% of patients, with the malar region, nose, and periorbital region being the most commonly affected sites. Pigmentation was clinically evident in 45.2% of cases. Surgical excision was the primary treatment modality (71.1% of patients). The median follow-up duration was 40 months (6-57 months). Recurrence occurred in five patients, with a longer disease-free survival period observed in the surgically treated group (55.58 ± 0.98 months) compared to patients treated with medical or destructive therapies (43.6 ± 3.482 months) (p = 0.003). Conclusion The data from this hospital-based study indicated a slight predilection for females among North Indian patients with BCC, with most cases occurring during their seventh decade of life. The condition commonly occurred on sun-exposed areas such as the malar region and nose, with a high percentage of pigmented lesions. Recurrence following surgical excision was rare, and overall treatment outcomes were favourable.</p>","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"210-216"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141996834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"'Trichophyton indotineae' is an inaccurate and pejorative term.","authors":"Shyam B Verma, Ananta Khurana, Philipp P Bosshard, Alexandra Kargl, Archana Singal, Abir Saraswat, Emanuella Guenova, Martin Schaller, Saumya Panda, Ali Rezaei-Matehkolaei, Ditte Marie L Saunte, Kabir Sardana, Ramesh M Bhat, Alireza Firooz, Esther Klonowski, Koushal Verma, Manjunath Shenoy, Rajeev Sharma, K A Seetharam, Silke Uhrlaß, Annette Kolb-Mäurer, Markus Vincent Starink, Mohammed Saiful Islam Bhuiyan, Nayani Priyangika Madarasingha, Arun Joshi, Sidra Saleem Khan, Jacek C Szepietowski, Uwe Wollina, Resham Vasani, Monisha Madhumita, Bhartendu Mehta, Valeska Padovese, Sudip Parajuli, Daniela Vanousova, Pietro Nenoff","doi":"10.25259/IJDVL_1793_2024","DOIUrl":"10.25259/IJDVL_1793_2024","url":null,"abstract":"","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"277-280"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143257202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of metastatic lung adenocarcinoma in a twenty-year-old skin graft site on the scalp: A case report.","authors":"Y H Kim, Y C Kim","doi":"10.25259/IJDVL_518_2023","DOIUrl":"10.25259/IJDVL_518_2023","url":null,"abstract":"","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"242-243"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138464039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trials.","authors":"Tao Wang, Wei Wu, Xiaoqing Zhang, Bin Gan, Yanfang Zhou, Xiaoyan Cheng","doi":"10.25259/IJDVL_14_2024","DOIUrl":"10.25259/IJDVL_14_2024","url":null,"abstract":"<p><p>Objectives Tofacitinib is used as an oral Janus-associated kinase (JAK) inhibitor acting on JAK1 and JAK3, in treating psoriatic disease. However, there is still no consensus on the optimal dosage and duration of tofacitinib. In this study, we aimed to evaluate the effects of tofacitinib in treating psoriatic disease. Methods A literature search was done utilising Cochrane library, Medline, EMBASE, Wiley Online library, Web of Science and BIOSIS Previews through December 18, 2022. We performed a meta-analysis of published original studies to assess the impact of tofacitinib in plaque psoriasis or psoriatic arthritis therapy based on seven randomised controlled trials (RCTs) involving 2,672 patients (receiving tofacitinib) and 853 controls (receiving placebo). Results Compared with placebo, the treatment of 5 mg twice-daily (BID) tofacitinib for 12 weeks is sufficient to significantly alleviate the main clinical manifestations of psoriasis [≥75% decrease in Psoriasis Area and Severity Index score (PASI 75): Risk ratio (RR)=4.38 (95% Confidence interval (CI) 2.51 to 7.64); ≥90% decrease in PASI score (PASI 90): RR=21.68 (95% CI 4.20 to 111.85); Physician's Global Assessment of 'clear' or 'almost clear' (PGA 0/1): RR=3.93 (95%CI 3.03 to 5.09)]. Interestingly, there was no significant difference in improvement in PGA 0/1 with 5 mg BID tofacitinib given for 16 weeks when compared with 5 mg BID tofacitinib for 12 weeks [RR=1.11 (95%CI 0.98 to 1.25)]. Additionally, the 5 mg BID tofacitinib for 16 weeks treatment schedule significantly increased the incidence of upper respiratory tract infection (URTI) [RR=1.89 (95%CI 1.06 to 3.38)] as compared to 5 mg BID tofacitinib for 12 weeks treatment schedule [RR=1.15 (95%CI 0.60 to 2.20)]. Conclusion The 5 mg BID tofacitinib for 12 weeks treatment significantly improved psoriasis without causing too many specific adverse events. This indicated that tofacitinib is an effective treatment plan for psoriatic disease by reasonably controlling dosage and dosing time.</p>","PeriodicalId":50376,"journal":{"name":"Indian Journal of Dermatology Venereology & Leprology","volume":" ","pages":"172-179"},"PeriodicalIF":3.2,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}